Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.4. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| GILD | KOLD | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $49.39 |
52-Week Low | $110.56 | $13.58 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KOLD, trading at $31.22, is down 2.19% over the past 24 hours. The technical outlook is bullish based on moving averages, with key support at $30 and resistance at $32. Recent news highlights natural gas market volatility, with futures influenced by weather forecasts and LNG export flows. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on natural gas price movements and demand shifts. While technical indicators suggest upward momentum, the lack of fundamental data and exposure to commodity price swings present risks. Investors should weigh the ETF's leveraged structure against market volatility for tactical positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
